Daily Judi: Wednesday, November 30, 2022
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
Following Eisai's presentation of findings yesterday in San Francisco, ABC News Australia features Eisai's and Biogen's new Alzheimer's treatment, Lecanemab, and reports the United States Food and Drug Administration (FDA) may expedite approval of the new drug. (Clinical Trials TV)
Ed Miseta, Chief Editor of Clinical Leader, details how major retailers, Walgreens, CVS, and Walmart, will improve participation in clinical trials.
To stave off possible device shortages, Swiss parliament voted to authorize United States FDA-approved medical devices. (Venous News)
“The final product that the client receives is fully configured to their trial, their forms, their workflow.”
–Jess, Program Manager
Judi speeds and improves the world's clinical trial workflows. Our cloud-based platform has 120,000 users across 168 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.